FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3167038652> ?p ?o ?g. }

• W3167038652 endingPage "e15555" @default.
• W3167038652 startingPage "e15555" @default.
• W3167038652 abstract "e15555 Background: Fruquintinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, is a new targeting anti-cancer agent for refractory metastatic colorectal cancer (mCRC). Promising antitumor effect of fruquintinib monotherapy was verified in a phase III FRESCO randomized study of mCRC patients, and only 30% patients were prior bevacizumab-treated. However, comprehensive effect evaluation of fruquintinib in mCRC patients who have previously failed in bevacizumab therapy were scarce. Methods: Forty patients with metastatic CRC who had previously failed at least 2 lines of standard regimen containing bevacizumab in Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine from March 2019 to February 2020 were enrolled. These patients were administrated with fruquintinib (5mg orally, once daily) in cycles of 3 weeks on/ 1 week off. Furthermore, the primary endpoint was overall survival (OS). Secondary endpoints mainly included progression-free survival (PFS), disease control rate (DCR), objective response rate (ORR), and safety profile. Statistical analyses were performed using IBM SPSS statistics software and ‘R’ statistical software with the ‘forest plot’ package. Subsequently, the variables were screened and verified through LASSO regression with the R software “glmnet” package. Results: The mOS was 8.1months (95%CI, 5.6667-12.8667), mPFS was 4.1833 months (95% CI, 3.5333-5.0667), and DCR was 65% (26 SD in 40 patients). Particularly, gender (HR: 7.11, 95%CI:1.86-27.16,P = 0.005), age (HR:0.91, 95%CI:0.85-0.98,P = 0.012), ECOG(HR:3.75, 95%CI:1.13-12.42,P = 0.03), medication duration (HR:0.62, 95%CI:0.48-0.81,P＜0.001),and the number of metastases(HR:2.95,95%CI:1.21-7.18,P = 0.017) identified the statistically significant association with OS. Eliminating the influence of time factor, ECOG and medication cycle obtained by Lasso regression were the risk factors for OS. The most frequently reported adverse events were mainly hypertension, proteinuria, hand-foot skin reaction, fatigue and diarrhea, and any new safety signals were not observed. Conclusions: Fruquintinib showed an acceptable safety profile and promising efficacy in patients with metastatic colorectal cancer failed in previously bevacizumab-based therapy. Future studies of fruquintinib should focus on identifying the patients most likely to benefit and on minimizing toxicity." @default.
• W3167038652 created "2021-06-22" @default.
• W3167038652 creator A5046676712 @default.
• W3167038652 date "2021-05-20" @default.
• W3167038652 modified "2023-10-16" @default.
• W3167038652 title "Fruquintinib in patients with metastatic colorectal cancer failed in previously bevacizumab-based therapy: A monocentric retrospective study." @default.
• W3167038652 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.e15555" @default.
• W3167038652 hasPublicationYear "2021" @default.
• W3167038652 type Work @default.
• W3167038652 sameAs 3167038652 @default.
• W3167038652 citedByCount "0" @default.
• W3167038652 crossrefType "journal-article" @default.
• W3167038652 hasAuthorship W3167038652A5046676712 @default.
• W3167038652 hasConcept C121608353 @default.
• W3167038652 hasConcept C126322002 @default.
• W3167038652 hasConcept C143998085 @default.
• W3167038652 hasConcept C168563851 @default.
• W3167038652 hasConcept C203092338 @default.
• W3167038652 hasConcept C2776694085 @default.
• W3167038652 hasConcept C2776999253 @default.
• W3167038652 hasConcept C2777802072 @default.
• W3167038652 hasConcept C2779998722 @default.
• W3167038652 hasConcept C2780739268 @default.
• W3167038652 hasConcept C2781413609 @default.
• W3167038652 hasConcept C526805850 @default.
• W3167038652 hasConcept C71924100 @default.
• W3167038652 hasConceptScore W3167038652C121608353 @default.
• W3167038652 hasConceptScore W3167038652C126322002 @default.
• W3167038652 hasConceptScore W3167038652C143998085 @default.
• W3167038652 hasConceptScore W3167038652C168563851 @default.
• W3167038652 hasConceptScore W3167038652C203092338 @default.
• W3167038652 hasConceptScore W3167038652C2776694085 @default.
• W3167038652 hasConceptScore W3167038652C2776999253 @default.
• W3167038652 hasConceptScore W3167038652C2777802072 @default.
• W3167038652 hasConceptScore W3167038652C2779998722 @default.
• W3167038652 hasConceptScore W3167038652C2780739268 @default.
• W3167038652 hasConceptScore W3167038652C2781413609 @default.
• W3167038652 hasConceptScore W3167038652C526805850 @default.
• W3167038652 hasConceptScore W3167038652C71924100 @default.
• W3167038652 hasIssue "15_suppl" @default.
• W3167038652 hasLocation W31670386521 @default.
• W3167038652 hasOpenAccess W3167038652 @default.
• W3167038652 hasPrimaryLocation W31670386521 @default.
• W3167038652 hasRelatedWork W16708841 @default.
• W3167038652 hasRelatedWork W1849033 @default.
• W3167038652 hasRelatedWork W19887974 @default.
• W3167038652 hasRelatedWork W20874565 @default.
• W3167038652 hasRelatedWork W21355150 @default.
• W3167038652 hasRelatedWork W265120 @default.
• W3167038652 hasRelatedWork W317545 @default.
• W3167038652 hasRelatedWork W3819646 @default.
• W3167038652 hasRelatedWork W6095507 @default.
• W3167038652 hasRelatedWork W9649811 @default.
• W3167038652 hasVolume "39" @default.
• W3167038652 isParatext "false" @default.
• W3167038652 isRetracted "false" @default.
• W3167038652 magId "3167038652" @default.
• W3167038652 workType "article" @default.